Regorafenib

Regorafenib is a targeted therapy medication commonly used for the treatment of certain cancers. It belongs to a group of drugs called kinase inhibitors, which work by blocking the activity of specific proteins in cancer cells, thereby slowing down their growth and spread.
Specifically, Regorafenib is indicated for the treatment of metastatic colorectal cancer in patients who have already undergone all other available treatment options, including chemotherapy and biological therapy. It has also demonstrated effectiveness in the treatment of gastrointestinal stromal tumors that have progressed after previous therapies.
Regorafenib is administered in the form of oral tablets and is typically taken once a day for two weeks, followed by one week of rest. This cycle is repeated, as directed by the healthcare provider, for as long as the medication continues to offer benefits without causing unbearable side effects.
Some potential side effects of Regorafenib may include fatigue, diarrhea, high blood pressure, and mouth sores, among others. It is essential for patients taking this medication to undergo regular monitoring by their healthcare provider to ensure that their treatment is effective and safe. They should also report any new symptoms, changes in their condition, or possible drug interactions to their healthcare professional.